Coya Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
COYA Nasdaq 2836 www.coyatherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Coya Therapeutics, Inc.

Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit - May 27th, 2026 6:00 am
Coya Therapeutics secures FDA fast track status for COYA 302 - May 14th, 2026 5:15 am
Hantavirus Outbreak Shows Need for Broad-Spectrum Antiviral Drugs - May 12th, 2026 6:35 am
Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update - May 12th, 2026 5:35 am
Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) - May 12th, 2026 5:30 am
NanoViricides to Participate at D. Boral Capital Global Conference in NYC - May 7th, 2026 6:35 am
NanoViricides’ Measles Treatment Granted Orphan Drug Designation by FDA - May 6th, 2026 6:35 am
Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS - Apr 9th, 2026 6:00 am
Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director - Apr 2nd, 2026 6:00 am
Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy - Mar 18th, 2026 6:00 am
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results - Mar 16th, 2026 6:00 am
Coya Therapeutics, Inc. (COYA) Upgraded to Buy: What Does It Mean for the Stock? - Feb 25th, 2026 10:00 am
Coya Therapeutics Details ALS Combo Immunotherapy Plan, Highlights Early Biomarker Signals in Webinar - Feb 17th, 2026 2:35 pm
Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial - Feb 10th, 2026 6:00 am
Coya Therapeutics to sell 2.522M shares at $4.40 in private placement - Jan 31st, 2026 6:15 am
Coya Therapeutics Announces $11.1 Million Private Placement - Jan 30th, 2026 6:00 am
Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders - Jan 20th, 2026 6:00 am
Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients - Jan 8th, 2026 6:00 am
Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD) - Jan 5th, 2026 6:00 am
Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS) - Dec 23rd, 2025 6:00 am